CAJ | 학술논문

目的：探讨β-七叶皂苷钠对多发性硬化（ MS）患者血清中超敏C反应蛋白（ HS-CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-17（IL-17）水平及日常生活质量的影响。方法：采用免疫荧光干式定量法、ELISA法测定加用β-七叶皂苷钠治疗的54例MS患者（观察组）及53例未加用者（对照组）入院治疗前及治疗后血清中HS-CRP、TNF-α、IL-17水平。两组分别于治疗前后进行扩充神经功能残疾量表（ EDSS ）评分。结果：两组治疗前HS-CRP、TNF-α、IL-17水平比较，差异均无统计学意义（ P＞0．05）；治疗后，两组均较治疗前明显降低（P＜0．01），但观察组较对照组降低更显著（P＜0．05）。两组治疗前EDSS评分比较，差异均无统计学意义（P＞0．05），治疗14 d后比较差异有统计学意义（P＜0．05）。结论：β-七叶皂苷钠可增强激素抑制HS-CRP、TNF-α、IL-17产生或释放的效果，进一步降低MS患者机体内炎症反应程度，达到治疗MS及提高其日常生活质量的目的。
목적：탐토β-칠협조감납대다발성경화（ MS）환자혈청중초민C반응단백（ HS-CRP）、종류배사인자-α（TNF-α）、백세포개소-17（IL-17）수평급일상생활질량적영향。방법：채용면역형광간식정량법、ELISA법측정가용β-칠협조감납치료적54례MS환자（관찰조）급53례미가용자（대조조）입원치료전급치료후혈청중HS-CRP、TNF-α、IL-17수평。량조분별우치료전후진행확충신경공능잔질량표（ EDSS ）평분。결과：량조치료전HS-CRP、TNF-α、IL-17수평비교，차이균무통계학의의（ P＞0．05）；치료후，량조균교치료전명현강저（P＜0．01），단관찰조교대조조강저경현저（P＜0．05）。량조치료전EDSS평분비교，차이균무통계학의의（P＞0．05），치료14 d후비교차이유통계학의의（P＜0．05）。결론：β-칠협조감납가증강격소억제HS-CRP、TNF-α、IL-17산생혹석방적효과，진일보강저MS환자궤체내염증반응정도，체도치료MS급제고기일상생활질량적목적。
Objective: To explore the influence of β-aescine sodium on the serum levels of HS-CRP, TNF-α, IL-17 and the quality of life in patients with MS .Methods:Quantitative immuno-cytochemistry and ELISA methods were used to determine the serum levels of HS-CRP, TNF-α, IL-17 in 54 MS patients treated with basic treatment and β-aescine sodium ( observation group ) and 53 MS patients treated without β-aescine sodium ( control group ) before and after treatment . The two groups before and after treatment were evaluated with extended neurological disability scale (EDSS) score respectively.Results:There was no significant difference of the levels of HS-CRP, TNF-α, IL-17 between observation group and control group .All the levels of HS-CRP, TNF-α, IL-17 decreased after treatment ( P<0 .01 ) , but observation group decreased much more than control group ( P<0 .05 ) .There was no significant difference of EDSS scores between observation and control groups before treatment (P>0.05), but EDSS scores of two groups were different after treatment (P<0.05).Conclusion:β-aescine sodium could enhance the effects of hormone on in-hibiting the production and release of HS-CRP, TNF-α, IL-17, further reduce inflammatory reac-tion in patients with MS , and improve the quality of life .